Condition (MeSH)
Bronchial Hyperreactivity
ClinicalTrials.gov lists 35 trials for Bronchial Hyperreactivity or a narrower condition beneath it. GlaxoSmithKline has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
35 of the 35 trials are tagged with Bronchial Hyperreactivity itself; the rest are tagged with a narrower condition beneath it.
When did Bronchial Hyperreactivity trials start? (19)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2024 | 2 |
| 2023 | 3 |
| 2022 | 3 |
| 2021 | 1 |
| 2019 | 2 |
| 2015 | 1 |
| 2014 | 1 |
| 2013 | 2 |
| 2012 | 1 |
| 2011 | 4 |
Showing 10 of 19 earlier years.
No forecast is made for this condition: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 35 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Bronchial Hyperreactivity trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 2 |
| Phase 4 | 3 |
| Not applicable | 15 |
| Observational | 13 |
How many Bronchial Hyperreactivity trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 3 |
| Completed | 24 |
| Terminated | 1 |
| Withdrawn | 1 |
| Unknown status | 6 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Bronchial Hyperreactivity trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| GlaxoSmithKline | 4 |
| Allergi- og Lungeklinikken, Elsinore | 2 |
| BL&H Co., Ltd | 1 |
| Federal State Budgetary Institution, Pulmonology Scientific Research Institute | 1 |
Which drugs are being tested for Bronchial Hyperreactivity? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| OPN-375 | 3 |
| Formoterol | 1 |
| Montelukast | 1 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg | 1 |
| Tiotropium bromide via (Spiriva® Handihaler®) | 1 |
| Salmeterol/Fluticasone propionate combination product | 1 |
| Blood Test | 1 |
| Nebulized IVX-0142 | 1 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Bronchial Hyperreactivity trials report? (7)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Worsening of asthma | 2 | 1 |
| Bone cyst | 1 | 1 |
| Cholecystitis | 1 | 1 |
| Colon diverticulitis | 1 | 1 |
| Hyperventilation | 1 | 1 |
Showing 5 of 7 adverse events.
Which publications cover Bronchial Hyperreactivity? (280)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM). | The European respiratory journal | 2022 | Yes |
| Asthma remission: what is it and how can it be achieved? | The European respiratory journal | 2022 | Yes |
| TLR5 Activation Exacerbates Airway Inflammation in Asthma. | Lung | 2020 | Yes |
| Predictors and reproducibility of exercise-induced bronchoconstriction in cold air. | BMC pulmonary medicine | 2019 | Yes |
| Effect of the S-nitrosoglutathione reductase inhibitor N6022 on bronchial hyperreactivity in asthma. | Immunity, inflammation and disease | 2018 | Yes |
Showing 5 of 280 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.